Search Immortality Topics:

Page 51«..1020..50515253..6070..»


Category Archives: Global News Feed

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 23 December 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Originally posted here:
Galapagos receives transparency notification from FMR LLC

Posted in Global News Feed | Comments Off on Galapagos receives transparency notification from FMR LLC

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or…

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA -

Read this article:
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or...

Posted in Global News Feed | Comments Off on Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or…

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

Proceeds extend cash runway to fund operations into early 2024

Go here to see the original:
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

Posted in Global News Feed | Comments Off on Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel

Originally posted here:
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

Posted in Global News Feed | Comments Off on SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.

Read more:
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

Posted in Global News Feed | Comments Off on ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider of private sector healthcare to veterans, to nationally expand its Beat Addiction Recovery Program.

More here:
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

Posted in Global News Feed | Comments Off on BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States